Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis

2017 ◽  
Vol 118 (12) ◽  
pp. 4782-4791 ◽  
Author(s):  
Shao-Nan Yu ◽  
Gui-Feng Liu ◽  
Xue-Feng Li ◽  
Bao-Hong Fu ◽  
Li-Xin Dong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Repair ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Dna Repair Genes ◽  
Small Cell Lung ◽  
Platinum Based Chemotherapy ◽  
Repair Genes

Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer

Lung Cancer ◽  
2011 ◽  
Vol 73 (1) ◽  
pp. 25-31 ◽  
Author(s):  
Sukki Cho ◽  
Min Jung Kim ◽  
Yi Young Choi ◽  
Seung Soo Yoo ◽  
Won Kee Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Repair ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Dna Repair Genes ◽  
Small Cell Lung ◽  
Tp53 Mutations ◽  
Repair Genes

scholarly journals Potential Functional Variants in DNA Repair Genes Are Associated with Efficacy and Toxicity of Radiotherapy in Patients with Non-Small-Cell Lung Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Zhiguang Yang ◽  
Zhaoyu Liu
Keyword(s):  
Lung Cancer ◽  
Dna Repair ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Dna Repair Genes ◽  
Small Cell Lung ◽  
Repair Gene ◽  
Repair Genes ◽  
Toxic Reactions

Background. Lung cancer is one of the leading causes of cancer-related deaths. Radiotherapy, either alone or with chemotherapy, is still the primary treatment for patients with non-small-cell lung cancer (NSCLC). There are variations in how patients with NSCLC respond to radiotherapy and how toxic the therapy is. DNA repair gene polymorphisms are related to cancer development; however, their association with radiotherapy outcomes remains unknown. We hypothesized that gDNA repair gene variation could affect the efficacy and toxicity of radiotherapy in patients with NSCLC. Methods. A total of 486 histologically confirmed patients with NSCLC were recruited from the Shengjing Hospital of China Medical University from July 2015 to September 2019. Eleven potentially functional single nucleotide polymorphisms (SNPs) in four DNA repair genes (XRCC1, XRCC2, XPD, and MSH2) were genotyped in these patients. A multiple factor logistic regression analysis was used to assess the association between these SNPs and the efficacy and toxicity of radiotherapy. Results. Three SNPs, rs25487 (XRCC1), rs3218556 (XRCC2), and rs13181 (XPD), were all significantly associated with the efficacy of radiotherapy. The allele frequencies of the rs25487 CC genotype (OR = 0.457, 95% CI = 0.259–0.804, p=0.006) and the rs3218556 AG or AA genotypes (AG genotype: OR = 0.664, 95% CI = 0.442–0.999, p=0.049; AA genotype: OR = 0.380, 95% CI = 0.181–0.795, p=0.008) were both significantly higher in the response group than in the nonresponse group. For rs13181, the radiotherapy efficacy was associated with the heterozygous genotype GT (OR = 1.663, 95% CI = 1.057–2.614,p=0.027). Statistically significant associations between radiation-induced toxic reactions and rs25487 (XRCC1), rs3218556 (XRCC2), and rs13181 (XPD) were also observed. The rs13181GT genotype was associated with lower toxic reactions than the TT genotype (OR = 1.680, 95% CI = 1.035–2.728,p=0.035). Conclusions. The variants rs25487 (XRCC1), rs3218556 (XRCC2), and rs13181 (XPD) all contribute to the efficacy and toxicity of radiotherapy in patients with NSCLC. Our findings may clarify the predictive value of DNA repair genes for prognosis in patients with NSCLC after radiotherapy. Further investigation of more genes and samples should be performed to confirm our findings.

scholarly journals Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells

2012 ◽  
Vol 27 (4) ◽  
pp. 959-964 ◽  
Author(s):  
BIN-CHUAN JI ◽  
CHIEN-CHIH YU ◽  
SU-TSO YANG ◽  
TE-CHUN HSIA ◽  
JAI-SING YANG ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Damage ◽  
Dna Repair ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Dna Repair Genes ◽  
Small Cell Lung ◽  
H460 Cells ◽  
Repair Genes

scholarly journals Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

2006 ◽  
Vol 17 (4) ◽  
pp. 668-675 ◽  
Author(s):  
R. de las Peñas ◽  
M. Sanchez-Ronco ◽  
V. Alberola ◽  
M. Taron ◽  
C. Camps ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Repair ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Dna Repair Genes ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Repair Genes

scholarly journals Polymorphisms of DNA repair genes and risk of non-small cell lung cancer

2005 ◽  
Vol 27 (3) ◽  
pp. 560-567 ◽  
Author(s):  
Shanbeh Zienolddiny ◽  
Daniele Campa ◽  
Helge Lind ◽  
David Ryberg ◽  
Vidar Skaug ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Repair ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Dna Repair Genes ◽  
Small Cell Lung ◽  
Repair Genes

Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature

2005 ◽  
Vol 23 (13) ◽  
pp. 2926-2936 ◽  
Author(s):  
Giannicola D'Addario ◽  
Melania Pintilie ◽  
Natasha B. Leighl ◽  
Ronald Feld ◽  
Thomas Cerny ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Hematologic Toxicity ◽  
Third Generation ◽  
Small Cell Lung ◽  
Platinum Based Chemotherapy ◽  
Combination Regimens

Purpose This meta-analysis was performed to compare the activity, efficacy and toxicity of platinum-based versus non-platinum-based chemotherapy in patients with advanced non-small-cell lung cancer. Methods Randomized phase II and III clinical trials comparing first-line palliative platinum-based chemotherapy with the same regimen without platinum or with platinum replaced by a nonplatinum agent were identified by electronic searches of Medline, Embase, and Cancerlit, and hand searches of relevant abstract books and reference lists. Response rates, 1-year survival, and toxicity were analyzed. Subgroups of trials using third-generation agents were compared. Results Thirty-seven assessable trials were identified including 7,633 patients. A 62% increase in the odds ratio (OR) for response was attributable to platinum-based therapy (OR, 1.62; 95% CI, 1.46 to 1.8; P < .0001). The 1-year survival rate was increased by 5% with platinum-based regimens (34% v 29%; OR, 1.21; 95% CI, 1.09 to 1.35; P = .0003). No statistically significant increase in 1-year survival was found when platinum therapies were compared to third-generation-based combination regimens (OR, 1.11; 95% CI, 0.96 to 1.28; P = .17). The toxicity of platinum-based regimens was significantly higher for hematologic toxicity, nephrotoxicity, and nausea and vomiting, but not for neurotoxicity, febrile neutropenia rate, or toxic death rate. Conclusion Response is significantly higher with platinum-containing regimens. One-year survival was not significantly prolonged when platinum-based therapies were compared with third-generation-based combination regimens. Toxicity is generally higher for platinum-based regimens.

Sign in / Sign up

Export Citation Format

Share Document